The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Positron Emission Tomography Is Superior to Computed Tomography Scanning for Response-Assessment After Radical Radiotherapy or Chemoradiotherapy in Patients With Non–Small-Cell Lung Cancer
Abstract
Purpose: To prospectively study the capacity of positron emission tomography (PET) and computed tomography (CT) to determine response soon after radical radiotherapy or chemoradiotherapy and, thereby, predict survival. PET is known to provide a more accurate estimate of true extent of disease than CT when used to stage non–small-cell lung cancer (NSCLC). Patients and Methods: Seventy-three patients with NSCLC underwent [18 F]fluorodeoxyglucose PET and CT scans before and after radical radiotherapy (n = 10) or chemoradiotherapy (n = 63). Follow-up PET scans were performed at a median of 70 days after radiotherapy. The median PET-CT interval was 1 day. Each patient had determinations of response to therapy made with PET and CT, categorized as complete response, partial response, no response, progressive disease, or nonassessable. Responses were correlated with subsequent survival. Results: Median survival after follow-up PET was 24 months. There was poor agreement between PET and CT responses (weighted kappa = 0.35), which were identical in only 40% of patients. There were significantly more complete responders on PET (n = 34) than CT (n = 10), whereas fewer patients were judged to be nonresponders (12 patients on PET v 20 on CT) or nonassessable (zero patients on PET v six on CT) by PET. Both CT and PET responses were individually significantly associated with survival duration; but on multifactor analysis that included the known prognostic factors of CT response, performance status, weight loss, and stage, only PET response was significantly associated with survival duration (P < .0001). Conclusion: In NSCLC, a single, early, posttreatment PET scan is a better predictor of survival than CT response, stage, or pretreatment performance status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Revisions in the International System for Staging Lung Cancer
Mountain, C. F. (1997) · Chest · doi:10.1378/chest.111.6.1710 · Cited by 4,565
Non-small Cell Lung Cancer Collaborative Group (1995) · BMJ · doi:10.1136/bmj.311.7010.899 · Cited by 2,850
A note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
Young, H., Baum, R., Cremerius, U., Herholz, K., Hoekstra, O., Lammertsma, A. A., Pruim, J., & Price, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00229-4 · Cited by 1,720
Dillman, R. O., Seagren, S. L., Propert, K. J., Guerra, J., Eaton, W. L., Perry, M. C., Carey, R. W., Frei, E. F., & Green, M. R. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231403 · Cited by 1,153
Weber, W. A., Ott, K., Becker, K., Dittler, H.-J., Helmberger, H., Avril, N. E., Meisetschläger, G., Busch, R., Siewert, J.-R., Schwaiger, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.12.3058 · Cited by 701
Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
Green, S., & Weiss, G. R. (1992) · Investigational New Drugs · doi:10.1007/bf00944177 · Cited by 610
McLoud, T. C., Bourgouin, P. M., Greenberg, R. W., Kosiuk, J. P., Templeton, P. A., Shepard, J. A., Moore, E. H., Wain, J. C., Mathisen, D. J., & Grillo, H. C. (1992) · Radiology · doi:10.1148/radiology.182.2.1732943 · Cited by 560
Cited by
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777
“In the Hicks qualitative PET criteria (Table 5), multiple lesions are assessed (76,84,92,141).”
BackgroundDelivering affordable cancer care in high-income countries
Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N. J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I. F., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70141-3 · Cited by 718
Self-citationProgress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Kelloff, G. J., Hoffman, J. M., Johnson, B., Scher, H. I., Siegel, B. A., Cheng, E. Y., Cheson, B. D., O'Shaughnessy, J., Guyton, K. Z., Mankoff, D. A., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2626 · Cited by 671
Wieder, H. A., Brücher, B. L. D. M., Zimmermann, F., Becker, K., Lordick, F., Beer, A., Schwaiger, M., Fink, U., Siewert, J. R., Stein, H. J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.122 · Cited by 454
Use of PET and PET/CT for Radiation Therapy Planning: IAEA expert report 2006–2007
MacManus, M., Nestle, U., Rosenzweig, K. E., Carrio, I., Messa, C., Belohlavek, O., Danna, M., Inoue, T., Deniaud-Alexandre, E., Schipani, S., et al. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2008.11.008 · Cited by 367
Self-citationDe Ruysscher, D., Faivre-Finn, C., Nestle, U., Hurkmans, C. W., Le Péchoux, C., Price, A., & Senan, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.3271 · Cited by 364
Worden, F. P., Kumar, B., Lee, J. S., Wolf, G. T., Cordell, K. G., Taylor, J. M. G., Urba, S. G., Eisbruch, A., Teknos, T. N., Chepeha, D. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7597 · Cited by 357
Positron Emission Tomography (PET) in Oncology
Gallamini, A., Zwarthoed, C., & Borra, A. (2014) · Cancers · doi:10.3390/cancers6041821 · Cited by 312
Avril, N., Sassen, S., Schmalfeldt, B., Naehrig, J., Rutke, S., Weber, W. A., Werner, M., Graeff, H., Schwaiger, M., & Kuhn, W. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.965 · Cited by 283
Sasaki, R., Komaki, R., Macapinlac, H., Erasmus, J., Allen, P., Forster, K., Putnam, J. B., Herbst, R. S., Moran, C. A., Podoloff, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.129 · Cited by 277
Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST
Costelloe, C. M., Chuang, H. H., Madewell, J. E., & Ueno, N. T. (2010) · Journal of Cancer · doi:10.7150/jca.1.80 · Cited by 270
The contribution of PET/CT to improved patient management
Ell, P. J. (2006) · The British Journal of Radiology · doi:10.1259/bjr/18454286 · Cited by 128
PET in the management of locally advanced and metastatic NSCLC
Grootjans, W., de Geus-Oei, L.-F., Troost, E. G. C., Visser, E. P., Oyen, W. J. G., & Bussink, J. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.75 · Cited by 97
Grootjans, W., de Geus-Oei, L.-F., Meeuwis, A. P. W., van der Vos, C. S., Gotthardt, M., Oyen, W. J. G., & Visser, E. P. (2014) · European Radiology · doi:10.1007/s00330-014-3362-z · Cited by 57
Developing biomarker-specific end points in lung cancer clinical trials
Neal, J. W., Gainor, J. F., & Shaw, A. T. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.222 · Cited by 51
Metadata
- Authors
- Mac Manus, M. P., Hicks, R. J., Matthews, J. P., McKenzie, A., Rischin, D., Salminen, E. K., & Ball, D. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-04-01
- Volume
- 21
- Issue
- 7
- Pages
- 1285-1292
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2042586311
- Cited by
- 439
- References
- 28
- FWCI
- 23.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.